Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen’s Aranesp Gets Broader Label

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA provides small boost for safety-challenged ESA.

You may also be interested in...

Amgen’s Anemia Drugs Weaken In First Quarter

“Trust us” on unchanged revenue guidance, CEO says.

Amgen’s Aranesp, Procrit CIA Indications Okay For Incurable Cancers - ODAC

Panel suggests new label saying the chemotherapy-induced anemia treatments are not indicated for patients with curable cancers, breast cancer or head and neck tumors.

Aranesp “Complete Response” Letter Seeks Additional Clinical Data On Monthly Dosing

Amgen hopes to respond to FDA request with already collected data.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts